Massmutual Trust Co. FSB ADV Increases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Massmutual Trust Co. FSB ADV lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,353 shares of the medical research company’s stock after buying an additional 261 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Edwards Lifesciences were worth $1,972,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. TIAA Trust National Association grew its stake in Edwards Lifesciences by 22.8% in the fourth quarter. TIAA Trust National Association now owns 11,149 shares of the medical research company’s stock worth $850,000 after purchasing an additional 2,072 shares during the period. DAVENPORT & Co LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $216,000. Capital Insight Partners LLC grew its stake in Edwards Lifesciences by 3.3% in the fourth quarter. Capital Insight Partners LLC now owns 49,895 shares of the medical research company’s stock worth $3,804,000 after purchasing an additional 1,589 shares during the period. Fulton Bank N.A. grew its stake in Edwards Lifesciences by 2.5% in the fourth quarter. Fulton Bank N.A. now owns 6,320 shares of the medical research company’s stock worth $482,000 after purchasing an additional 156 shares during the period. Finally, Prime Capital Investment Advisors LLC grew its stake in Edwards Lifesciences by 33.1% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 5,353 shares of the medical research company’s stock worth $408,000 after purchasing an additional 1,331 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Activity

In other news, VP Daniel J. Lippis sold 857 shares of Edwards Lifesciences stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total value of $73,359.20. Following the transaction, the vice president now directly owns 23,890 shares in the company, valued at approximately $2,044,984. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, VP Daniel J. Lippis sold 857 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total transaction of $73,359.20. Following the transaction, the vice president now directly owns 23,890 shares in the company, valued at approximately $2,044,984. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 5,625 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $90.45, for a total value of $508,781.25. Following the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,764,242.45. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,099 shares of company stock worth $2,680,879. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Down 0.2 %

Shares of EW stock traded down $0.11 on Monday, reaching $60.72. 7,175,256 shares of the company’s stock were exchanged, compared to its average volume of 3,956,146. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $36.58 billion, a PE ratio of 25.76, a P/E/G ratio of 2.57 and a beta of 1.11. The company’s fifty day simple moving average is $85.32 and its 200 day simple moving average is $86.58.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. The company had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. Edwards Lifesciences’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the business posted $0.66 EPS. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.71 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of several analyst reports. Robert W. Baird downgraded Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $102.00 to $70.00 in a report on Thursday, July 25th. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. TD Cowen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $100.00 to $70.00 in a report on Thursday, July 25th. JPMorgan Chase & Co. downgraded Edwards Lifesciences from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $105.00 to $72.00 in a report on Thursday, July 25th. Finally, Baird R W downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Fourteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $82.10.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.